ArticleJournal of clinical microbiology2009
Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis.
Article in Journal of clinical microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Guideline
- A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Guideline
- Review
- Draft genome sequence ofMicrobiology resource announcements · 2026Article
- The repertoire of yeast species from human clinical samples in the United Kingdom 2016-2022: epidemiology, clinical relevance, and fluconazole resistance.Microbiology spectrum · 2026Article
- Native Valve Endocarditis Due toJournal of fungi (Basel, Switzerland) · 2026Article
- Molecular insights into ochratoxin A biodegradation.Biologia futura · 2025Review
- Access to Substituted Tricyclic Heteroarenes by an Oxidative Cyclization Reaction and Their Antifungal Performance.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The first report of Apiotrichum mycotoxinivorans isolation from human cerebrospinal fluid.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Fungal Colonization of the Airways of Patients with Cystic Fibrosis: the Role of the Environmental Reservoirs.Mycopathologia · 2024Review
- Review
- Oral dysbiosis and its linkage with SARS-CoV-2 infection.Microbiological research · 2022Article
- Bronchial Artery-Pulmonary Artery Shunt byInfection and drug resistance · 2022Article
- Complete Genome Sequencing and Comparative Analysis of the Clinically-DerivedFrontiers in cellular and infection microbiology · 2022Article
- Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis.Mycopathologia · 2018Review
- Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis.Mycopathologia · 2018Article
- Article
- Advances in Biodetoxification of Ochratoxin A-A Review of the Past Five Decades.Frontiers in microbiology · 2018Review
- Emergence of Trichosporon mycotoxinivorans (Apiotrichum mycotoxinivorans) invasive infections in Latin America.Memorias do Instituto Oswaldo Cruz · 2017Article
- In Vitro Activity of Berberine Alone and in Combination with Antifungal Drugs Against Planktonic Forms and Biofilms of Trichosporon Asahii.Mycopathologia · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
This report describes the molecular epidemiology, in vitro susceptibility, colonial and microscopic morphologies, and biochemical features of Trichosporon mycotoxinivorans, a newly recognized pathogen that appears to have a propensity for patients with cystic fibrosis. The index patient died with histologically documented Trichosporon pneumonia complicating cystic fibrosis. This is also the first report of disease caused by a Trichosporon species in a nontransplant patient with cystic fibrosis. As T. mycotoxinivorans has not previously been recognized as a respiratory pathogen, the significance of its recovery from sputum samples was not initially appreciated. Genetic analysis of archived clinical samples found three additional cases of T. mycotoxinivorans infection which had previously been identified as other members of the genus. An additional isolate of T. mycotoxinivorans was identified from a clinical sample on initial testing. Three of these four cases were also patients with cystic fibrosis. All isolates had MICs at 48 h of amphotericin B of > or = 1 microg/ml and of echinocandins of > or = 16 microg/ml, but they displayed various susceptibilities to the triazoles. In summary, Trichosporon mycotoxinivorans is a newly recognized human pathogen that is associated with cystic fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.